Using Of Human Menopausal Gonadotropin Hormone Versus Oral Ovarian Stimulation Agents In Induction Of Ovulation In Women With Polycystic Ovary Syndrome In Salah Al-Deen Hospital/Tikrit City

Abstract

Polycystic ovary syndrome is a common cause of an ovulatory infertility. Drugs like Aromatase inhibitors, Human menopausal gonadotropin, used for ovulation induction. The aim of this study was carried out to compare the therapeutic effects of gonadotropin hormone versus oral ovarian stimulating agents. A prospective randomized controlled clinical trial was carried out in the Salahdeen general hospital in Tikrit from 1st Feb-30th August 2020. About 75 PCOs patients enrolled randomly in the study and divided equally into 3 groups as below: Group A treated with (75 IU intramuscular HMG gonadotropin) daily for 5 days starting Day 2 of menstrual cycle. Group B treated with oral clomiphene citrate 100 mg daily for 5 days starting Day 2 of menstrual cycle. Group C treated with oral Letrezole 5 mg daily for 5 days starting Day 2 of menstrual cycle. Multiple mature follicles were obtained commonly by HMG, followed by Letrozole, then Clomiphene, this relation was statistically significant. Endometrial thickness was higher among those treated with HMG (10.5±1.7) than those treated by Clomiphene (9.03±0.9), and then treated by letrozole (8.5±1.2). This is a significant difference in ET value between Clomiphene, letrozole, and HMG. Chemical pregnancy (early pregnancy loss that occurs shortly after implantation may account to 50-75% of all miscarriages) was higher among those treated with HMG (20%), while it was (16%) of those treated with Clomiphene, and (12%) of the Letrozole group, this relation was statistically not significant. In conclusion, HMG had the highest response rate, followed by Letrozole, and Clomiphene. The multiple mature follicles was obtained commonly by HMG, followed by Letrozole, then Clomiphene.